Here's something that may actually be priced at free market value. Former hedge fund manager and Turing Pharmaceutical CEO Martin Shkreli is now auctioning off an opportunity to punch him in the face.
Bruce Y. Lee, Contributor, Forbes
Tue, 09/27/2016 - 8:16pm
Here's something that may actually be priced at free market value. Former hedge fund manager and Turing Pharmaceutical CEO Martin Shkreli is now auctioning off an opportunity to punch him in the face.